Melatonina

Target

Cerca gli articoli con queste parole nel campo target

Azione della melatonina

Cerca gli articoli con riferimento a queste azioni della melatonina

Anno: 1993

Titolo: Vitiligo: where do we stand?

Riferimento:
Pigment Cell Res. 1993 Mar;6(2):61-72.

Azione della melatonina:
Abnormalities in a putative melatonin receptor on melanocytes.

Target:
Several different pathogenetic mechanisms.
Titolo: [Melatonin, a clinically important hormone?]

Riferimento:
Dtsch Med Wochenschr. 1983 Mar 25;108(12):470-4. Review.

Azione della melatonina:
No abstract available.

Target:
No abstract available.

Anno: 1994

Titolo: Interaction between melatonin and estradiol on morphological and morphometric features of MCF-7 human breast cancer cells

Riferimento:
J Pineal Res. 1994 May;16(4):215-22.

Azione della melatonina:
Antitumor effect through a cell-cycle-specific mechanism by delaying the entry of cells into mitosis.

Target:
Smaller cell and nuclear sizes
Titolo: Animal studies on the role of 50/60-Hertz magnetic fields in carcinogenesis

Riferimento:
Life Sci. 1994;54(21):1531-43. Review.

Azione della melatonina:
Reduction of circulating levels of melatonin.

Target:
50/60-Hz MF
Titolo: Melatonin concentrations in pineal organ culture are suppressed by sera from tumor-bearing mice

Riferimento:
J Pineal Res. 1994 Aug;17(1):17-9.

Azione della melatonina:
Melatonin rhythmicity is suppressed in cancer patients.

Target:
Plasma borne tumor-associated factor (TAMF).
Titolo: Breast cancer mortality among female electrical workers in the United States

Riferimento:
J Natl Cancer Inst. 1994 Jun 15;86(12):921-5.

Azione della melatonina:
Exposure to extremely low-frequency electromagnetic fields reduces the pineal gland's nocturnal production of the hormone melatonin.

Target:
Electric or magnetic fields.
Titolo: A randomised study with subcutaneous low-dose interleukin 2 alone vs interleukin 2 plus the pineal neurohormone melatonin in advanced solid neoplasms other than renal cancer and melanoma

Riferimento:
Br J Cancer. 1994 Jan;69(1):196-9.

Azione della melatonina:
The concomitant administration of MLT (40 mg day orally) may increase the efficacy of low-dose IL-2 subcutaneous therapy.Tumour objective regression rate was 11/41 vs 1/39, P < 0.001.

Target:
Interleukin 2 (IL-2) plus MLT.
Titolo: Modulation of estrogen receptor mRNA expression by melatonin in MCF-7 human breast cancer cells.

Riferimento:
Mol Endocrinol. 1994 Dec;8(12):1681-90.

Azione della melatonina:
Antiproliferative actions of Mlt are mediated through the suppression of the transcription of ER gene.

Target:
Estrogen receptor (ER) mRNA
Titolo: Serial transplants of 7,12-dimethylbenz[a]anthracene-induced mammary tumors in Fischer rats as model system for human breast cancer. 3. Quantitative ultrastructural studies of the pinealocytes and plasma melatonin concentrations in rats bearing an advance

Riferimento:
Biol Signals. 1994 Nov-Dec;3(6):302-6.

Azione della melatonina:
Plasma melatonin concentrations in tumor-bearing rats killed at 3.00 h were suppressed by 35% when compared to the control animals killed at the same time.

Target:
Plasma melatonin concentrations
Titolo: Differences between pulsatile or continuous exposure to melatonin on MCF-7 human breast cancer cell proliferation

Riferimento:
Cancer Lett. 1994 Sep 30;85(1):105-9.

Azione della melatonina:
Antiproliferative effect was obtained by sequential exposure to 10(-9) M/10(-11)M 12/12h melatonin, which mimics the physiological rhythm of serum melatonin concentration.

Target:
Physiological rhythm/serum melatonin concentration

A.I.A.N. - Modena

Melatonina

Anno: 1993

Anno: 1994

Pagine